Prediction of prognosis in children with medulloblastoma by using immunohistochemical analysis and tissue microarray

Journal of Neurosurgery: Pediatrics

Volumn 1, Issue 3, 2008, Pages 196-205

  Shim, Kyu Won ^a   Joo, Sun Young ^a   Kim, Se Hoon ^a   Choi, Joong Uhn ^a   Kim, Dong Seok ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Medulloblastoma; Prognosis; Proliferation index; TrkC antibody

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 3; NEUROTROPHIN 3 RECEPTOR;

APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHILDHOOD CANCER; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; MULTIMODALITY CANCER THERAPY; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RECURRENT CANCER; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TISSUE MICROARRAY; TUMOR VOLUME;

ADOLESCENT; ADULT; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CEREBELLAR NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; FORECASTING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEDULLOBLASTOMA; MICROARRAY ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RECEPTOR, ERBB-3; RECEPTOR, TRKC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 40449083172     PISSN: 19330707     EISSN: 19330715     Source Type: Journal    
DOI: 10.3171/PED/2008/1/3/196     Document Type: Article

References (40)

1. Brown HG, Kepner JL, Perlman EJ, Friedman HS, Strother DR, Duffner PK, et al: Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 94:552-560, 2002
2. Brown HG, Kepner JL, Perlman EJ, Friedman HS, Strother DR, Duffner PK, et al: "Large cell/anaplastic" medulloblastomas: a Pediatric Oncology Group Study. J Neuropathol Exp Neurol 59:857-865, 2000
3. Chang CH, Housepian EM, Herbert C Jr: An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 93:1351-1359, 1969
4. Coffin CM, Braun JT, Wick MR, Dehner LP: A clinicopathologic and immunohistochemical analysis of 53 cases of medulloblastoma with emphasis on synaptophysin expression. Mod Pathol 3:164-170, 1990
5. Eberhart CG, Kratz J, Wang Y, Summers K, Stearns D, Cohen K, et al: Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 63:441-449, 2004
6. Ellison DW, Clifford SC, Gajjar A, Gilbertson RJ: What's new in neuro-oncology? Recent advances in medulloblastoma. Eur J Paediatr Neurol 7:53-66, 2003
7. Giangaspero H, Kleihues P, Pietsch T, Trojanowski JQ: Medulloblastoma, in Kleihues P, Cavenee WK (eds): Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC Press, 2000, pp 129-137
8. Gilbertson R, Wickramasinghe C, Hernan R, Balaji V, Hunt D, Jones-Wallace D, et al: Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 85:705-712, 2001
9. Giordana MT, Cavalla P, Dutto A, Borsotti L, Chiò A, Schiffer D: Is medulloblastoma the same tumor in children and adults? J Neurooncol 35:169-176, 1997
10. Giordana MT, D'Agostino C, Pollo B, Silvani A, Ferracini R, Paiolo A, et al: Anaplasia is rare and does not influence prognosis in adult medulloblastoma. J Neuropathol Exp Neurol 64:869-874, 2005
11. Giordana MT, Schiffer P, Schiffer D: Prognostic factors in medulloblastoma. Childs Nerv Syst 14:256-262, 1998
12. Grotzer MA, Janss AJ, Fung K, Biegel JA, Sutton LN, Rorke LB, et al: TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol 18:1027-1035, 2000
13. Grotzer MA, Janss AJ, Phillips PC, Trojanowski JQ: Neurotrophin receptor TrkC predicts good clinical outcome in medulloblastoma and other primitive neuroectodermal brain tumors. Klin Padiatr 212:196-199, 2000
14. Haslam RH, Lamborn KR, Becker LE, Israel MA: Tumor cell apoptosis present at diagnosis may predict treatment outcome for patients with medulloblastoma. J Pediatr Hematol Oncol 20:520-527, 1998
15. Hayashi K, Motoi M, Nose S, Horie Y, Akagi T, Ogawa K, et al: An immunohistochemical study on the distribution of glial fibrillary acidic protein, S-100 protein, neuron-specific enolase, and neurofilament in medulloblastomas. Acta Pathol Jpn 37:85-96, 1987
16. Hoos A, Cordon-Cardo C: Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest 81:1331-1338, 2001
17. Kallioniemi OP, Wagner U, Kononen J, Sauter G: Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 10:657-662, 2001
18. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61:215-229, 2002
19. Korshunov A, Savostikova M, Ozerov S: Immunohistochemical markers for prognosis of average-risk pediatric medulloblastomas. The effect of apoptotic index, TrkC, and c-myc expression. J Neurooncol 58:271-279, 2002
20. Kramer JH, Crowe AB, Larson DA, Sneed PK, Gutin PH, Mc-Dermott MW, et al: Neuropsychological sequelae of medulloblastoma in adults. Int J Radiat Oncol Biol Phys 38:21-26, 1997
21. Langlois NE, Eremin O, Heys SD: Apoptosis and prognosis in cancer: rationale and relevance. J R Coll Surg Edinb 45:211-219, 2000
22. Maraziotis T, Perentes E, Karamitopoulou E, Nakagawa Y, Gessaga EC, Probst A, et al: Neuron-associated class III beta-tubulin isotype, retinal S-antigen, synaptophysin, and glial fibrillary acidic protein in human medulloblastomas: a clinicopathological analysis of 36 cases. Acta Neuropathol 84:355-363, 1992
23. McLendon RE, Friedman HS, Fuchs HE, Kun LE, Bigner SH: Diagnostic markers in paediatric medulloblastoma: a Paediatric Oncology Group Study. Histopathology 34:154-162, 1999
24. McManamy CS, Lamont JM, Taylor RE, Cole M, Pearson AD, Clifford SC, et al: Morphophenotypic variation predicts clinical behavior in childhood non-desmoplastic medulloblastomas. J Neuropathol Exp Neurol 62:627-632, 2003
25. Miralbell R, Tolnay M, Bieri S, Probst A, Sappino AP, Berchtold W, et al: Pediatric medulloblastoma: prognostic value of p53, bcl-2, Mib-1, and microvessel density. J Neurooncol 45:103-110, 1999
26. Nam DH, Wang KC, Kim YM, Chi JG, Kim SK, Cho BK: The effect of isochromosome 17q presence, proliferative and apoptotic indices, expression of c-erbB-2, bcl-2 and p53 proteins on the prognosis of medulloblastoma. J Korean Med Sci 15:452-456, 2000
27. Packer RJ, Goldwein J, Nicholson HS, Vezina LG, Allen JC, Ris MD, et al: Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children's Cancer Group study. J Clin Oncol 17:2127-2136, 1999
28. Packer RJ, Sutton LN, D'Angio G, Evans AE, Schut L: Management of children with primitive neuroectodermal tumors of the posterior fossa/medulloblastoma. Pediatr Neurosci 12:272-282, 1985
29. Packer RJ, Sutton LN, Rorke LB, Littman PA, Sposto R, Rosenstock JG, et al: Prognostic importance of cellular differentiation in medulloblastoma of childhood. J Neurosurg 61:296-301, 1984
30. Pizem J, Cör A, Zadravec Zaletel L, Popovic M: Prognostic significance of apoptosis in medulloblastoma. Neurosci Lett 381:69-73, 2005
31. Ray A, Ho M, Ma J, Parkes RK, Mainprize TG, Ueda S, et al: A clinicobiological model predicting survival in medulloblastoma. Clin Cancer Res 10:7613-7620, 2004
32. Ris MD, Packer R, Goldwein J, Jones-Wallace D, Boyett JM: Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study. J Clin Oncol 19:3470-3476, 2001
33. Rutkauskiene G, Labanauskas L: Treatment of patients of highrisk group of medulloblastoma with the adjuvant lomustine, cisplatin, and vincristine chemotherapy. Medicina (Kaunas) 41:1026-1034, 2005
34. Savitz SI, Rosenbaum DM: Apoptosis in neurological disease. Neurosurgery 42:555-574, 1998
35. Schubert TE, Cervos-Navarro J: The histopathological and clinical relevance of apoptotic cell death in medulloblastomas. J Neuropathol Exp Neurol 57:10-15, 1998
36. Segal RA, Goumnerova LC, Kwon YK, Stiles CD, Pomeroy SL: Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci U S A 91:12867-12871, 1994
37. Son EI, Kim IM, Kim DW, Yim MB, Kang YN, Lee SS, et al: Immunohistochemical analysis for histopathological subtypes in pediatric medulloblastomas. Pathol Int 53:67-73, 2003
38. Tajima Y, Molina RP Jr, Rorke LB, Kaplan DR, Radeke M, Feinstein SC, et al: Neurotrophins and neuronal versus glial differentiation in medulloblastomas and other pediatric brain tumors. Acta Neuropathol (Berl) 95:325-332, 1998
39. Tamm I, Schriever F, Dörken B: Apoptosis: implications of basic research for clinical oncology. Lancet Oncol 2:33-42, 2001
40. Woodburn RT, Azzarelli B, Montebello JF, Goss IE: Intense p53 staining is a valuable prognostic indicator for poor prognosis in medulloblastoma/central nervous system primitive neuroectodermal tumors. J Neurooncol 52:57-62, 2001